Medical management of side effects related to CAR T cell therapy in hematologic malignancies

Expert Review of Hematology

Volumn 9, Issue 6, 2016, Pages 511-513

  Namuduri, Manjusha ^a   Brentjens, Renier J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

CAR T cell; CD19; chimeric antigen receptor; cytokine release syndrome; immunotherapy

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; INTERLEUKIN 6; CD19 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR;

CELL THERAPY; CYTOKINE RELEASE SYNDROME; DIAGNOSTIC VALUE; DNA MODIFICATION; EDITORIAL; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOGENICITY; INTENSIVE CARE; MACROPHAGE ACTIVATION SYNDROME; ONCOLOGIST; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR LYSIS SYNDROME; ADOPTIVE IMMUNOTHERAPY; BIOLOGICAL THERAPY; HEMATOLOGIC DISEASE;

ANTIGENS, CD19; CELL- AND TISSUE-BASED THERAPY; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; RECEPTORS, ANTIGEN, T-CELL;

EID: 84969730158     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1080/17474086.2016.1183479     Document Type: Editorial

References (20)

1. R.J.Brentjens, K.J.Curran Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen. Hematol Am Soc Hematol Educ Program. 2012;2012:143–151.
2. M.L.Davila, I.Riviere, X.Wang, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra225.
3. S.A.Grupp, M.Kalos, D.Barrett, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–1518.
4. J.N.Kochenderfer, M.E.Dudley, S.A.Feldman, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709–2720.
5. D.S.Ritchie, P.J.Neeson, A.Khot, et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther. 2013;21(11):2122–2129.
6. X.J.Xu, H.Z.Zhao, Y.M.Tang. Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials. Leuk Lymphoma. 2013;54(2):255–260.
7. M.Kalos, B.L.Levine, D.L.Porter, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.
8. D.W.Lee, R.Gardner, D.L.Porter, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–195.
9. R.Brentjens, R.Yeh, Y.Bernal, et al. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther. 2010;18(4):666–668.
10. R.J.Brentjens, M.L.Davila, I.Riviere, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra138.
11. Y.Tang, X.Xu, H.Song, et al. Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome. Br J Haematol. 2008;143(1):84–91.
12. X.-J.Xu, Y.-M.Tang, H.Song, et al. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatr. 2012;160(6):984-90.e1.
13. G.Janka, U.Zur Stadt. Familial and acquired hemophagocytic lymphohistiocytosis. Hematol Am Soc Hematol Educ Program. 2005;82–88.
14. S.L.Maude, D.Barrett, D.T.Teachey, et al. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20(2):119–122.
15. D.W.Lee, J.N.Kochenderfer, M.Stetler-Stevenson, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–528.
16. D.L.Porter, B.L.Levine, M.Kalos, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725–733.
17. R.J.Brentjens, I.Riviere, J.H.Park, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817–4828.
18. S.L.Maude, N.Frey, P.A.Shaw, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517.
19. D.L.Porter, W.T.Hwang, N.V.Frey, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139.
20. X.Wang, W.-C.Chang, C.W.Wong, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood. 2011;118(5):1255–1263.